Physician profile
Robert Beckham
NPI 1851896971
$3,527.12
in general payments reported to CMS, 2019-2025
23 companies · $792 in 2025
The $792 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $706 · 2023: $943 · 2024: $909 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.57 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $977.53 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $721.74 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $352.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $350.29 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $221.46 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.98 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $97.14 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $89.99 | 2024-2025 | Rexulti |
| Pfizer INC. | $68.25 | 2024-2025 | |
| Axsome Therapeutics, INC. | $63.57 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $60.64 | 2021-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $60.42 | 2022-2024 | Myrbetriq, Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $57.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.49 | 2022-2023 | Xifaxan |
| Shield Therapeutics INC | $48.65 | 2023-2025 | Accrufer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $26.52 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $19.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.88 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $16.34 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.31 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $16.10 | 2025 | Fanapt |
| Ultragenyx Pharmaceutical INC. | $15.60 | 2022 | |
| Amarin Pharma, INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Beckham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.